{"id":47303,"date":"2022-08-15T20:02:24","date_gmt":"2022-08-15T18:02:24","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\/"},"modified":"2022-08-15T20:02:24","modified_gmt":"2022-08-15T18:02:24","slug":"xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\/","title":{"rendered":"Xlear Files Amended Answer to the Government\u2019s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear\u2019s Use as Additional Layer of Protection"},"content":{"rendered":"<div>\n<p>SALT LAKE CITY&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/nasal?src=hash\" target=\"_blank\" rel=\"noopener\">#nasal<\/a>&#8211;Xlear has filed an Amended Answer in response to the U.S. Government\u2019s lawsuit against the company. According to Nathan Jones, Xlear\u2019s CEO, the Amended Answer serves three main purposes: First, it provides the Court with still more data that supports the statements Xlear made that nasal hygiene is an additional layer of protection in fighting COVID-19, that our public health officials are ignoring; Second, it lays out in greater detail how the U.S. Government\u2019s lawsuit is an effort to censor science that doesn\u2019t comport with the Government\u2019s vaccine-myopic, failing strategy to combat the disease; Third, it documents how experts, including Dr. Fauci, are increasingly saying the nose is the critical place to fight the virus.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220815005519\/en\/1544206\/5\/XlearPro.active_2tone_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220815005519\/en\/1544206\/21\/XlearPro.active_2tone_logo.jpg\"><\/a><\/p>\n<p>\nXlear\u2019s Amended Answer provides two new studies that support the statements Xlear made about the use of its nasal spray as a potential additional layer of protection against COVID-19:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nA new in vitro study found that use of a simple saline solution stops SAR-CoV2 viral replication in human lung tissue. Rafael R. G. Machado, Talita Glaser, Danielle B. Araujo, Lyvia Lintzmaier Petiz, Danielle B. L. Oliveira, Giuliana S. Durigon, Alessandra L. Leal, Jo\u00e3o Renato R. Pinho, Luis C. S. Ferreira, Henning Ulrich, Edison L. Durigon, and Cristiane Rodrigues Guzzo, ACS Pharmacology &amp; Translational Science 2021 4 (5), 1514-1527, available at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F34651104%2F&amp;esheet=52813993&amp;newsitemid=20220815005519&amp;lan=en-US&amp;anchor=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F34651104%2F&amp;index=1&amp;md5=5325e849a9ef07ce5dfd2baab59248e7\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/pubmed.ncbi.nlm.nih.gov\/34651104\/<\/a>. Nate Jones, CEO of Xlear noted, \u201cThe Government agrees, Xlear is a saline nasal solution. This <i>in vitro<\/i> study documents that saline nasal hygiene helps stop COVID-19 from replicating in nasal tissue\u2014which we know is where the virus typically grows and infects people.\u201d\n<\/li>\n<li>\nNew <i>in silico<\/i> research determined that compounds of grapefruit seed extract (GSE) were effective inhibitors of the SARS-CoV-2 virus. Belmina Saric, et al., In silico analysis of selected components of grapefruit seed extract SARS-CoV-2 main protease, EuroBiotech J., 5 (special issue 1); 2021, 5. DOI: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdoi.org%2F10.2478%2Febtj-2021-0015&amp;esheet=52813993&amp;newsitemid=20220815005519&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdoi.org%2F10.2478%2Febtj-2021-0015&amp;index=2&amp;md5=f0eafef92354c7085b7bed68251680bb\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/doi.org\/10.2478\/ebtj-2021-0015<\/a>. Most importantly, these experts concluded natural GSE\u2014which is a component of Xlear\u2014was more effective than synthetic versions of the compound.\n<\/li>\n<\/ul>\n<p>\nJones continued: \u201cThese aren\u2019t the Random Clinical Trials the Government is so focused on\u2014but you can\u2019t deny the mounting wall of evidence that nasal hygiene should be used as an additional layer of protection against COVID-19. Moreover, the Government recently announced that it won\u2019t require Random Clinical Trials for the new variant vaccines\u2014that requirement seems to only apply when it is convenient for the Government.\u201d\n<\/p>\n<p>\nJones also noted that the SARS-CoV-2 variants are all strains of coronavirus, and experts have long recommended nasal hygiene to combat coronaviruses. \u201cAs a rule, prevention methods and symptom-reduction modalities (e.g., over the counter drugs, handwashing) are not variant specific; they are used against colds and flus on the whole, many caused by coronaviruses. One countermeasure that experts, including the US Government, recommend to fight the common cold, including coronavirus-infections, is nasal hygiene.\u201d DeGeorge KC, Ring DJ, Dalrymple SN. Treatment of the Common Cold. Am Fam Physician. 2019 Sep 1;100(5):281-289. PMID: 31478634, reprinted by NIH as authority at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F31478634%2F&amp;esheet=52813993&amp;newsitemid=20220815005519&amp;lan=en-US&amp;anchor=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F31478634%2F&amp;index=3&amp;md5=2493212895fb5e0301b5337bf1c3e348\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/pubmed.ncbi.nlm.nih.gov\/31478634\/<\/a> (\u201cTreatments with proven effectiveness for cold symptoms [coronavirus infections] in adults include over-the-counter analgesics, zinc, nasal decongestants . . . The only established safe and effective treatments for children are . . . nasal saline irrigation . . .\u201d). \u201cIt\u2019s commonsense, something our Government\u2019s response to COVID seems to be lacking,\u201d Jones added.\n<\/p>\n<p>\nAs part of its efforts to silence Xlear, the Government asked the Utah Federal Court to preclude Xlear from filing the Amended Answer. The Federal Court ruled in Xlear\u2019s favor. The Court\u2019s ruling specifically noted: \u201cThe court shares some concern here, as expressed by Defendants, that the underlying purpose [in the Government\u2019s motion to prevent Xlear\u2019s Amended Answer] is to prevent discovery into disputed facts that may lend support to Defendants\u2019 proposed amendments.\u201d \u201cIn other words, the Government is doing everything they can stonewall us from shining a light on their failed COVID-19 response,\u201d Jones added.\n<\/p>\n<p>\n\u201cA new more infectious and more dangerous variant is sweeping the nation. Infections are up. Hospitalizations are up. Deaths are up. At the same time, fewer and fewer people are willing to get vaccinated for the third, fourth, who knows how many times,\u201d Jones noted. \u201cIt\u2019s obvious we need a new, broader\u2014&#8217;vaccine-plus\u2019\u2014approach. But rather than educate people, the Government is suing us in retaliation for talking about the science. I\u2019m deeply afraid even telling the Court about these new studies will bring more Government retaliation, however in the face of the Government\u2019s failure what choice is there. When science gives way to dogma, people suffer,\u201d Jones concluded.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nXlear Media Relations<br \/>\n<br \/>Nathan Jones<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#x69;&#108;t&#x6f;&#58;m&#x65;&#100;&#x69;&#x61;&#64;&#x78;&#108;e&#x61;&#114;&#x2e;&#x63;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#109;&#101;&#x64;i&#97;&#x40;&#x78;l&#101;&#x61;&#x72;&#46;&#99;&#x6f;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>SALT LAKE CITY&#8211;(BUSINESS WIRE)&#8211;#nasal&#8211;Xlear has filed an Amended Answer in response to the U.S. Government\u2019s lawsuit against the company. According to Nathan Jones, Xlear\u2019s CEO, the Amended Answer serves three main purposes: First, it provides the Court with still more data that supports the statements Xlear made that nasal hygiene is an additional layer of &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47303","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Xlear Files Amended Answer to the Government\u2019s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear\u2019s Use as Additional Layer of Protection - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xlear Files Amended Answer to the Government\u2019s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear\u2019s Use as Additional Layer of Protection - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SALT LAKE CITY&#8211;(BUSINESS WIRE)&#8211;#nasal&#8211;Xlear has filed an Amended Answer in response to the U.S. Government\u2019s lawsuit against the company. According to Nathan Jones, Xlear\u2019s CEO, the Amended Answer serves three main purposes: First, it provides the Court with still more data that supports the statements Xlear made that nasal hygiene is an additional layer of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-15T18:02:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220815005519\/en\/1544206\/21\/XlearPro.active_2tone_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Xlear Files Amended Answer to the Government\u2019s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear\u2019s Use as Additional Layer of Protection\",\"datePublished\":\"2022-08-15T18:02:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\\\/\"},\"wordCount\":812,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220815005519\\\/en\\\/1544206\\\/21\\\/XlearPro.active_2tone_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\\\/\",\"name\":\"Xlear Files Amended Answer to the Government\u2019s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear\u2019s Use as Additional Layer of Protection - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220815005519\\\/en\\\/1544206\\\/21\\\/XlearPro.active_2tone_logo.jpg\",\"datePublished\":\"2022-08-15T18:02:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220815005519\\\/en\\\/1544206\\\/21\\\/XlearPro.active_2tone_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220815005519\\\/en\\\/1544206\\\/21\\\/XlearPro.active_2tone_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xlear Files Amended Answer to the Government\u2019s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear\u2019s Use as Additional Layer of Protection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Xlear Files Amended Answer to the Government\u2019s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear\u2019s Use as Additional Layer of Protection - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\/","og_locale":"en_US","og_type":"article","og_title":"Xlear Files Amended Answer to the Government\u2019s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear\u2019s Use as Additional Layer of Protection - Pharma Trend","og_description":"SALT LAKE CITY&#8211;(BUSINESS WIRE)&#8211;#nasal&#8211;Xlear has filed an Amended Answer in response to the U.S. Government\u2019s lawsuit against the company. According to Nathan Jones, Xlear\u2019s CEO, the Amended Answer serves three main purposes: First, it provides the Court with still more data that supports the statements Xlear made that nasal hygiene is an additional layer of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-15T18:02:24+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220815005519\/en\/1544206\/21\/XlearPro.active_2tone_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Xlear Files Amended Answer to the Government\u2019s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear\u2019s Use as Additional Layer of Protection","datePublished":"2022-08-15T18:02:24+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\/"},"wordCount":812,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220815005519\/en\/1544206\/21\/XlearPro.active_2tone_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\/","url":"https:\/\/pharma-trend.com\/en\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\/","name":"Xlear Files Amended Answer to the Government\u2019s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear\u2019s Use as Additional Layer of Protection - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220815005519\/en\/1544206\/21\/XlearPro.active_2tone_logo.jpg","datePublished":"2022-08-15T18:02:24+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220815005519\/en\/1544206\/21\/XlearPro.active_2tone_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220815005519\/en\/1544206\/21\/XlearPro.active_2tone_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/xlear-files-amended-answer-to-the-governments-lawsuit-on-covid-19-statements-provides-still-more-data-in-support-of-xlears-use-as-additional-layer-of-protection\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Xlear Files Amended Answer to the Government\u2019s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear\u2019s Use as Additional Layer of Protection"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47303"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47303\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47303"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}